| NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism |
The FDA d esignation m arks a s ignificant m ilestone in the d evelopment of a n ovel t reatment for a r are n eurodevelopmental d isorder |
globenewswire.com |
2025-04-21 20:05:00 |
Czytaj oryginał (ang.) |
| NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board |
Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer's Disease Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer's Disease |
globenewswire.com |
2025-04-15 20:05:00 |
Czytaj oryginał (ang.) |
| Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home |
GARDEN CITY, N.Y., April 09, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the publication of its scientific article, “A Pilot Study to Assess the Effect of Intermittent Inhaled Nitric Oxide as Treatment of Nontuberculous Mycobacteria Lung Infection” in Annals of the American Thoracic Society, an online peer-reviewed journal. The article is available online at (click here). |
globenewswire.com |
2025-04-09 20:05:00 |
Czytaj oryginał (ang.) |
| Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site |
As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iNO technology As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iNO technology |
globenewswire.com |
2025-03-31 12:00:00 |
Czytaj oryginał (ang.) |
| Beyond Oil Announces Start of Commercialization of India Distribution Agreement; First Payment Received |
Beyond Oil announces successful initiation of first order under new distribution agreement focusing on Indian markets, with full payment received for upcoming 6T shipment Beyond Oil announces successful initiation of first order under new distribution agreement focusing on Indian markets, with full payment received for upcoming 6T shipment |
globenewswire.com |
2025-03-24 18:30:00 |
Czytaj oryginał (ang.) |
| NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy |
First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, including Alzheimer's disease and brain cancers, and a subsidiary of Beyond Air (NASDAQ: XAIR), has secured an initial $2 million in equity financing from private investors as part of a larger funding round. This investment will accelerate the preclinical development of NeuroNOS's small-molecule drug, designed as an injectable or oral treatment for children with autism. |
globenewswire.com |
2025-03-24 18:05:00 |
Czytaj oryginał (ang.) |
| Beyond Oil Announces First Distribution Agreement in Portugal |
Distribution Agreement with Serious Formula Ltd. establishes Beyond Oil's presence in the Portuguese market; Agreement includes a five-year expected minimum purchase commitment plan amounting to €1.13 million Distribution Agreement with Serious Formula Ltd. establishes Beyond Oil's presence in the Portuguese market; Agreement includes a five-year expected minimum purchase commitment plan amounting to €1.13 million |
globenewswire.com |
2025-03-19 18:30:00 |
Czytaj oryginał (ang.) |
| Beyond Oil Announces Strategic Investment at a Premium to Market Price by Clal Insurance, a Leading Israeli Institutional Investor, as Part of Potential Uplisting to a Senior Exchange |
Clal Insurance to invest approximately CAD $10.5 million in Beyond Oil at a 10% premium to its stock market trading price, with potential follow-on investment through the exercise of warrants; Beyond Oil commits to pursuing a potential uplisting to a senior exchange in Canada or the U.S. Clal Insurance to invest approximately CAD $10.5 million in Beyond Oil at a 10% premium to its stock market trading price, with potential follow-on investment through the exercise of warrants; Beyond Oil commits to pursuing a potential uplisting to a senior exchange in Canada or the U.S. |
globenewswire.com |
2025-03-12 14:08:00 |
Czytaj oryginał (ang.) |
| Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH |
Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 countries Initial international orders for LungFit PH systems have been received for four countries GARDEN CITY, N.Y., March 11, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, announced the expansion of its global distribution channels for LungFit PH with several new distribution agreements that will cover four countries, including France, Romania, Turkey and Morocco. |
globenewswire.com |
2025-03-11 09:30:00 |
Czytaj oryginał (ang.) |
| Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences |
GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the Roth 37th Annual Growth Stock Conference being held March 16-18, 2025 in Laguna, CA and the Jones Healthcare and Technology Innovation Conference being held April 8-9, 2025 in Las Vegas, NV. |
globenewswire.com |
2025-03-06 18:05:00 |
Czytaj oryginał (ang.) |
| Beyond Oil Enters Indian Market with Significant Distribution Agreement |
Strategic agreement to introduce Beyond Oil's innovative frying oil filtration solution to restaurants across India Strategic agreement to introduce Beyond Oil's innovative frying oil filtration solution to restaurants across India |
globenewswire.com |
2025-02-28 18:30:00 |
Czytaj oryginał (ang.) |
| Beyond Oil Announces First Distribution Agreement in South Africa |
New Agreement with Minrosolve Proprietary Marks an Important Milestone in Beyond Oil's Accelerating Global Expansion New Agreement with Minrosolve Proprietary Marks an Important Milestone in Beyond Oil's Accelerating Global Expansion |
globenewswire.com |
2025-02-26 18:30:00 |
Czytaj oryginał (ang.) |
| Beyond Oil Delivers First Shipment of 5.4T to T&J Oil Under Australian Distribution Agreement |
Initial Delivery Marks Milestone in Beyond Oil's Expansion into Australia; Agreement Includes Minimum Commitments of US$4.9M Over Five Years Initial Delivery Marks Milestone in Beyond Oil's Expansion into Australia; Agreement Includes Minimum Commitments of US$4.9M Over Five Years |
globenewswire.com |
2025-02-18 18:20:00 |
Czytaj oryginał (ang.) |
| Beyond Air, Inc. (XAIR) Q3 2025 Earnings Call Transcript |
Beyond Air, Inc. (NASDAQ:XAIR ) Q3 2025 Results Conference Call February 10, 2025 4:30 PM ET Company Participants Corey Davis - Investor Relations, LifeSci Advisors Steve Lisi - Chairman and Chief Executive Officer Doug Larson - Chief Financial Officer Conference Call Participants Jason Wittes - Roth Partners Sam Eiber - BTIG Jason Bednar - Piper Sandler Justin Walsh - JonesTrading Yale Jen - Laidlaw & Company Operator Good afternoon, and welcome everyone to the Beyond Air Financial Results Call for the Fiscal Quarter Ended December 31, 2024. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-02-10 21:25:17 |
Czytaj oryginał (ang.) |
| Beyond Air, Inc. (XAIR) Reports Q3 Loss, Tops Revenue Estimates |
Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.50 per share a year ago. |
zacks.com |
2025-02-10 20:21:08 |
Czytaj oryginał (ang.) |
| Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update |
Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH ® in Europe and Market Authorization in Australia; international shipments to commence later this year Conference call at 4:30 p.m. ET today, February 10 th GARDEN CITY, New York, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced its financial results for the fiscal third quarter ended December 31, 2024, and provided a corporate update. |
globenewswire.com |
2025-02-10 18:05:00 |
Czytaj oryginał (ang.) |
| Beyond Oil Delivers January Order Sized 10.8T to Latitude as Part of Master Distribution Agreement |
Further to the Company's Recent Announcement, Beyond Oil Reports the Successful Delivery of its First Order; Beyond Oil received January's payment under the previously announced Agreement which includes minimum commitments of US$8.3M for 2025 Further to the Company's Recent Announcement, Beyond Oil Reports the Successful Delivery of its First Order; Beyond Oil received January's payment under the previously announced Agreement which includes minimum commitments of US$8.3M for 2025 |
globenewswire.com |
2025-02-05 18:20:00 |
Czytaj oryginał (ang.) |
| Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement |
GARDEN CITY, N.Y., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced it received a notification from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has been granted an additional 180-day compliance period, or until August 4, 2025 to regain compliance with Nasdaq's minimum bid price rule (Rule 5550(a)(2)). The notification has no immediate effect on the listing of the Company's common stock, and the common stock will continue to trade on the Nasdaq Capital Market under the symbol "XAIR." |
globenewswire.com |
2025-02-05 11:29:00 |
Czytaj oryginał (ang.) |
| Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast |
GARDEN CITY, N.Y., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the fiscal third quarter 2025 ended December 31, 2024 on Monday, February 10, 2025 after the market closes. |
globenewswire.com |
2025-01-27 18:05:00 |
Czytaj oryginał (ang.) |
| Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia |
GARDEN CITY, N.Y., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the LungFit® PH has received market authorization from the Australian Therapeutic Goods Administration (TGA) for sale as a Class IIb medical device to deliver nitric oxide, a vasodilator, generated by the device into the inspiratory limb of the patient breathing circuit of a ventilator in a way that provides a constant concentration of nitric oxide, as set by the user, to the patient throughout the inspired breath. |
globenewswire.com |
2025-01-24 11:15:00 |
Czytaj oryginał (ang.) |
| National Advertising Division Recommends Beyond Air Discontinue or Modify Comparative Safety Claims for its iNO Products |
In a Fast-Track SWIFT challenge brought by competitor Vero Biotech, Inc., BBB National Programs' National Advertising Division recommended that Beyond Air, Inc. discontinue the challenged comparative superiority safety claims for its iNO (inhaled nitric oxide) products or modify its advertising to avoid conveying the message that Beyond Air's products are safer than Vero's and/or that Vero's products are unsafe. In a Fast-Track SWIFT challenge brought by competitor Vero Biotech, Inc., BBB National Programs' National Advertising Division recommended that Beyond Air, Inc. discontinue the challenged comparative superiority safety claims for its iNO (inhaled nitric oxide) products or modify its advertising to avoid conveying the message that Beyond Air's products are safer than Vero's and/or that Vero's products are unsafe. |
globenewswire.com |
2024-12-09 13:00:00 |
Czytaj oryginał (ang.) |
| Bears are Losing Control Over Beyond Air (XAIR), Here's Why It's a 'Buy' Now |
Beyond Air (XAIR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
zacks.com |
2024-12-09 12:56:13 |
Czytaj oryginał (ang.) |
| Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy |
HAMILTON, Bermuda, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that the Israeli Ministry of Health (IMOH) has approved the use of Low Volume UNO (LV UNO) in a Phase 1b clinical trial of LV UNO in combination with anti-PD-1 therapy. The trial will be conducted at four sites in Israel and patient screening will begin in the first quarter of 2025. |
globenewswire.com |
2024-12-03 18:05:00 |
Czytaj oryginał (ang.) |
| Beyond Air Receives CE Mark in Europe for the LungFit® PH System |
Indication covers newborn infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension to improve right ventricular function in conjunction with heart surgery |
globenewswire.com |
2024-12-02 09:30:00 |
Czytaj oryginał (ang.) |
| NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board |
Professor Kornberg will assist in accelerating the development of treatments for Autism Spectrum Disorder and potentially other neurological disorders Professor Kornberg will assist in accelerating the development of treatments for Autism Spectrum Disorder and potentially other neurological disorders |
globenewswire.com |
2024-11-26 09:30:00 |
Czytaj oryginał (ang.) |
| Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference |
GARDEN CITY, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of Nitric Oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings and a fireside chat at the Piper Sandler 36th Annual Healthcare Conference being held December 3-5, 2024 in New York. |
globenewswire.com |
2024-11-14 18:05:00 |
Czytaj oryginał (ang.) |
| Beyond Air, Inc. (XAIR) Q2 2025 Earnings Call Transcript |
Beyond Air, Inc. (NASDAQ:XAIR ) Q2 2025 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Corey Davis - Investor Relations, LifeSci Advisors Steve Lisi - Chairman and Chief Executive Officer Douglas Larson - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH MKM Partners Marie Thibault - BTIG Yale Jen - Laidlaw & Company Matt Kaplan - Ladenburg Thalmann Operator Good afternoon, and welcome, everyone to the Beyond Air Financial Results Call for the Fiscal Quarter Ending September 30, 2024. At this time, participants are in a listen-only mode. |
seekingalpha.com |
2024-11-11 21:56:53 |
Czytaj oryginał (ang.) |
| Beyond Air, Inc. (XAIR) Reports Q2 Loss, Lags Revenue Estimates |
Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.51 per share a year ago. |
zacks.com |
2024-11-11 20:16:20 |
Czytaj oryginał (ang.) |
| Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update |
Revenues increased 17% compared to the previous quarter ended June 30, 2024 Strengthened balance sheet is expected to provide sufficient cash runway through June 2026 Completed a $20.6 million private placement offering with multiple healthcare-focused institutional funds and Company insiders Retired $17.5 million in debt from Avenue Capital and entered into a $11.5 million loan agreement with an insider-led investor group Conference call scheduled for 4:30 p.m. ET today, November 11 th GARDEN CITY, N.Y. |
globenewswire.com |
2024-11-11 18:05:00 |
Czytaj oryginał (ang.) |
| Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast |
GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes. |
globenewswire.com |
2024-10-29 18:22:00 |
Czytaj oryginał (ang.) |
| Beyond Oil Expands into Western Europe with Purchase Order from Mister Noodles Restaurant Chain in Spain |
Initial Order for All 20 of the Chain's Restaurants is Beyond Oil's First Direct Sale in Western Europe VANCOUVER, BC and KIBBUTZ YIFAT, ISRAEL / ACCESSWIRE / October 15, 2024 / Beyond Oil Ltd. (CSE:BOIL)(OTCQB:BEOLF) ("Beyond Oil" or the "Company"), a food-tech innovation company dedicated to reducing health risks associated with fried food while lowering operational costs, minimizing waste, and enhancing sustainability, is pleased to announce that it has hit another commercial milestone with its first direct purchase order in Western Europe. |
accesswire.com |
2024-10-15 11:30:00 |
Czytaj oryginał (ang.) |
| Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting |
HAMILTON, Bermuda, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced being selected to present two poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024, which is scheduled to be held November 6–10 at the George R. Brown Convention Center in Houston, Texas. Abstracts are scheduled to be released to SITC registrants on November 5, 2024, 9:00 AM U.S. ET. |
globenewswire.com |
2024-10-07 11:00:00 |
Czytaj oryginał (ang.) |
| Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks |
Revolutionary inhaled nitric oxide technology set to reach broader healthcare systems Revolutionary inhaled nitric oxide technology set to reach broader healthcare systems |
globenewswire.com |
2024-10-02 11:30:00 |
Czytaj oryginał (ang.) |
| Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed |
GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, is proud to announce the deployment of its groundbreaking LungFit® PH system to the U.S. Naval Hospital Guam. This partnership, made possible through collaboration with TrillaMed, marks a significant advancement in the neonatal critical care unit, offering enhanced care for newborns in need of respiratory support. |
globenewswire.com |
2024-09-27 11:34:00 |
Czytaj oryginał (ang.) |
| Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital |
– Retiring $17.5 million in Avenue Capital debt and entering into a $11.5 million loan agreement with an insider-led investor group – |
globenewswire.com |
2024-09-27 11:32:00 |
Czytaj oryginał (ang.) |
| Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules |
– Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 – – Retiring $17.5 million in Avenue Capital debt, aided by $11.5 million in new debt from insider-led group; eliminates $12 million in scheduled debt payments through June 2026 – – Avenue Capital, current insiders, and select group of healthcare-focused investment funds participated in the equity offering – GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors, as well as Company insiders. |
globenewswire.com |
2024-09-27 11:30:00 |
Czytaj oryginał (ang.) |
| Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference |
GARDEN CITY, N.Y., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings at the 3rd Annual ROTH Healthcare Opportunities Conference to be held at the Metropolitan Club in New York on October 9th. |
globenewswire.com |
2024-09-23 12:00:00 |
Czytaj oryginał (ang.) |
| Beyond Air, Inc. (XAIR) Reports Q1 Loss, Misses Revenue Estimates |
Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.45 per share a year ago. |
zacks.com |
2024-08-06 23:57:13 |
Czytaj oryginał (ang.) |
| Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia |
GARDEN CITY, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”), today announced the publication of its scientific article, “A safety evaluation of intermittent high-dose inhaled nitric oxide in viral pneumonia due to COVID-19: a randomized clinical study” in Scientific Reports, an online peer-reviewed journal from the publishers of Nature. The article is freely available online at https://www.nature.com/articles/s41598-024-68055-w. |
globenewswire.com |
2024-07-31 20:15:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for July 25th |
BSVN, OKTA, SVM, SFIX and XAIR have been added to the Zacks Rank #1 (Strong Buy) List on July 25, 2024. |
zacks.com |
2024-07-25 11:55:48 |
Czytaj oryginał (ang.) |